Alan Davidson

Alan Davidson

Auto-generated profile, based on publicly available information

Alan Davidson

University of Cape Town

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
ADAlan Md Davidson
Alan Md Davidson
RWRosalinda D. Wainwright
Rosalinda D. Wainwright
DSDavid K. Stones
David K. Stones
MKMariana Kruger
Mariana Kruger
MHMarc Hendricks
Marc Hendricks
Daniela Cristina StefanDaniela Cristina Stefan
Daniela Cristina Stefan
Objectives: In 2008 the South African Children’s Cancer Study Group decided to review the epidemiology, management, and chemotherapy response of HIV-positive children with malignancy. Methods: This is a retrospective analysis of data collected from the records of HIV-positive children diagnosed with malignancy at 7 university-based pediatric oncology units serving 8 of the 9 provinces in South Africa. Results: Two hundred eighty-eight HIV-positive children were diagnosed with 289 malignancies between 1995 and 2009. Age at diagnosis ranged from 17 days to 18.64 years; median 5.79 years. Of the 220 HIV-associated malignancies, there were 97 Kaposi sarcomas, 61 Burkitt lymphomas, 47 other B-cell lymphomas including 2 primary central nervous system lymphomas, 12 Hodgkin lymphomas, and 3 leiomyosarcomas. Sixty-nine patients presented with non–AIDS-defining malignancies. More than 80% presented with advanced disease. Most patients (76.7%) were naive to antiretroviral therapy; 22.2% did not have access because it only became available in public hospitals in 2004. One hundred ninety-seven children were treated with curative intent; 91 received palliative care due to advanced malignancy and/or advanced HIV disease. Nearly one third had coexisting pathology, mostly tuberculosis. Overall survival for the whole group was 33.7%, but was 57.8% for those treated with antiretroviral therapy and chemotherapy. Conclusions: The study shows more Kaposi sarcoma and fewer primary central nervous system lymphomas among HIV-positive children than that is reported in the developed world, but confirms a higher incidence of non-Burkitt B-cell lymphoma than in HIV-negative children. The high number of non–AIDS-defining malignancies underscores the prevalence of HIV-AIDS in South Africa. The overall survival should improve with universal access to antiretrovirals and earlier diagnosis.

27 November 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
DBDeepak Bansal
Deepak Bansal
ADAlan Davidson
Alan Davidson
ESEddy Supriyadi
Eddy Supriyadi
FNFestus Njuguna
Festus Njuguna
RRRaul C. Ribeiro
Raul C. Ribeiro
Gertjan KaspersGertjan Kaspers
Gertjan Kaspers
In low‐ and middle‐income countries (LMICs), limited resources, suboptimal risk stratification, and disproportionate patient‐to‐infrastructure ratio result in low survival of patients with acute myeloid leukemia (AML). A high incidence of relapse, inherent to the biology, renders management arduous. The challenge of treating AML in LMICs is of balancing the intensity of myelosuppressive chemotherapy, which appears necessary for cure, with available supportive care, which influences treatment‐related mortality. The recommendations outlined in this paper are based on published evidence and expert opinion. The principle of this adapted protocol is to tailor treatment to available resources, reduce preventable toxic death, and direct limited resources toward those children who are most likely to be cured.

14 September 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
JGJennifer Ann Geel
Jennifer Ann Geel
JCJulia Challinor
Julia Challinor
NRNeil Ranasinghe
Neil Ranasinghe
KMKhumo Hope Myezo
Khumo Hope Myezo
KEKatherine Claire Eyal
Katherine Claire Eyal
LHLaila Hessissen
Laila Hessissen
Introduction: Inalignment with the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC), the International Society of Pediatric Oncology initiated a program to map global pediatric oncology services. As survival rates in Africa are low and data are scant, this continent was mapped first to identify areas with greatest need.Methods: Beginning November 2018, an electronic survey was sent to all known stakeholders, followed by email communications and internet searches to verify data. Availability of pediatric oncologists, chemotherapy, surgical expertise, and radiotherapy was correlated with geographic region, World Bank income status, Universal Health Coverage, population < 15 and < 24 years, percentage of gross domestic product spent on healthcare, and Human Development Index (HDI).Results: Responses were received from 48/54 African countries. All three treatment modalities were reportedly available in 9/48 countries, whereas seven countries reported no pediatric oncology services. Negative correlations were detected between provision of all three services and geographic region (P = 0.01), younger median population age (P = 0.002), low‐income country status (P = 0.045), and lower HDI (P < 0.001).Conclusion: This study provides a comprehensive overview of pediatric oncology care in Africa, emphasizing marked disparities between countries: some have highly specialized services, whereas others have no services. A long‐term strategy to eliminate disparities in African pediatric cancer care should be aligned with the WHO GICC aims and facilitated by SIOP Africa.Meeting abstracts: SIOP maps pediatric oncology services in Africa to address inequalities in childhood cancer services. Geel J, Ranasinghe N, Davidson A, Challinor J, Howard S, Wollaert S, Myezo K, Renner L, Hessissen L, Bouffet E. 51st Annual Congress of the International Society of Paediatric Oncology (SIOP), Lyon, France, October 2019. Pediatric Blood and Cancer Vol 66 S219‐S219. Pediatric cancer care in Africa: SIOP Global Mapping Program report on economic and population indicators.

1 December 2022 in JCO Global Oncology
Verified
Journal Article
Open access
SBSimon Bailey
Simon Bailey
ADAlan Davidson
Alan Davidson
JPJeannette Parkes
Jeannette Parkes
UTUri Tabori
Uri Tabori
AFAnthony Figaji
Anthony Figaji
Steven CliffordSteven Clifford
Steven Clifford
Pragmatic ways to apply molecular innovation to childhood brain cancer diagnosis and therapy in LMICs

11 March 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
DMDaniel C Moreira
Daniel C Moreira
IQIbrahim Qaddoumi
Ibrahim Qaddoumi
SSSusan Spiller
Susan Spiller
TBThomas W Bouldin
Thomas W Bouldin
ADAlan Davidson
Alan Davidson
JCJason Chiang
Jason Chiang
Pediatric-type diffuse low-grade gliomas (pLGG) harboring recurrent genetic alterations involving MYB or MYBL1 are closely related tumors. Detailed treatment and outcome data of large cohorts are still limited. This study aimed to comprehensively evaluate pLGG with these alterations to define optimal therapeutic strategies. We retrospectively reviewed details of pLGG with MYB or MYBL1 alterations from patients treated or referred for pathologic review at St. Jude Children's Research Hospital. Tumor specimens were centrally reviewed, and clinical data were collated. Thirty-three patients (18 male; median age, 5 y) were identified. Two tumors had MYBL1 alterations; 31 had MYB alterations, MYB::QKI fusion being the most common (n=10, 30%). Most tumors were in the cerebral hemispheres (n=22, 67%). Two patients (6%) had metastasis at diagnosis. The median follow-up was 6.1 years. The 5-year event-free survival (EFS) rate was 81.3±8.3%; the 5-year overall survival (OS) rate was 96.4±4.1%. Patients receiving a near-total or gross-total resection had a 5-year EFS of 100%; those receiving a biopsy or subtotal resection had a 5-year EFS rate of 56.6±15.2% (p<0.01). No difference in EFS was observed based on location, histology, or molecular alterations. However, the tumors that progressed or metastasized may have distinct methylation profiles with evidence of activation of the MAPK and PI3K/AKT/mTOR pathways. pLGG with MYB/MYBL1 alterations have good outcomes. Our findings suggest that surgical resectability is a crucial determinant of EFS. Further characterization is required to identify optimal treatment strategies for progressive tumors.

1 April 2012 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
JSJuli Renate MBChB (WITS) Switala
Juli Renate MBChB (WITS) Switala
MHMarc MD Hendricks
Marc MD Hendricks
ADAlan MD Davidson
Alan MD Davidson
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease in children and presents many diagnostic difficulties. Without prompt intervention, the disease typically runs a rapidly fatal course. Diagnostic criteria were proposed by the Histiocyte Society in 1991 and have since been modified. Included in these criteria is a ferritin level >500 mcg/L2. Although not diagnostic, a high ferritin level is highly suggestive of HLH. Serum ferritin assays are more accessible and cost-effective compared with other biochemical markers, particularly in resource-limited settings. Fifteen patients with HLH were treated at Red Cross War Memorial Children’s Hospital between 1991 and 2010. Hyperferritinemia was a consistently reliable finding (93%) compared with either serum fibrinogen or triglycerides, which were elevated in only half of the patients. It is our contention that analysis of a complete blood count and serum ferritin (in addition to clinical criteria and tissue examination of marrow and/or cerebrospinal fluid) is probably the single most cost-effective and clinically helpful means to make the diagnosis of HLH when laboratory access is limited.